Estimation of lymphocytes, tumor necrosis factor, and interleukin-17 levels in postmenopausal obese women with type 2 diabetes

Abstract

Diabetes mellitus type 2 is a complex metabolic disorder characterized by hyperglycemia, a physiologically abnormal condition represented by persistently elevated blood glucose levels resulting from abnormalities in insulin secretion, insulin action, or both, and manifested in a chronic and heterogeneous manner in the metabolism of carbohydrates, fats, and proteins. The study included measuring the levels of lymphocytes, tumor necrosis factor alpha, and interleukin 17 among obese postmenopausal women with type 2 diabetes attending Samarra General Hospital and private clinics in Samarra city, Salah al-Din governorate. The study began from mid-October 2022 to the beginning of February 2023 on a study population whose ages ranged from 55-85 years. The total number of them was 120 women, 30 of them were healthy women who were considered as control group and 90 of them were the patient groups. The levels of lymphocytes were assessed using the CBC Mindary BS-5000. And measuring the levels of each tumor necrosis factor-α-tumor necrosis factor and interleukin 17 (IL17) using the radioenzyme assay technique (ELISA), , In the patients group, there was a significant increase (P≤0.05) in the levels of (lymphocytes, tumor necrosis factor, and interleukin-17) in the patients group compared to the control group.